Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07723963 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy

StatusNot Yet Recruiting
PhasePhase 2/3
Started2026-09-18
View on ClinicalTrials.gov ↗

Amendment history

2026-09-01
Study Status, Contacts/Locations v2
Trial sites expanded: 10 → 19 locations
Start date2026-09-01→2026-09-18
2026-07-22
Study Identification, Study Status v1
Study title-69 characters
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy
2026-07-20
Original filing
Jazz Pharmaceuticals
34 trials monitored
See 1 trial at risk
Epilepsy
723 trials monitored
See 41 trials at risk
This study is being conducted to evaluate the safety and efficacy of JZP926 capsule in participants with Juvenile Myoclonic Epilepsy (JME).
Trial Details
NCT Number NCT07723963
Lead Sponsor Jazz Pharmaceuticals
Conditions Juvenile Myoclonic Epilepsy
Enrollment 260 participants
Start Date 2026-09-18
Primary Completion 2028-08-01 (estimated)
Study Completion 2028-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-09-02